Synthace’s relocation to White City marks a significant stride in the area’s development as a biotechnology hub.
This move signifies both the expansion of a dynamic company and the bolstering of the local economy, with new employment opportunities on the horizon.
A New Era for White City
Synthace, a pioneering biotech firm, has announced its relocation to White City Place, contributing to the area’s growing status as a hub for life sciences. This move is expected to create 40 new jobs, which will potentially double within a year, illustrating Synthace’s rapid growth trajectory.
Compared to its former location in St Pancras, the new 13,000 square feet premises in the WestWorks building offers Synthace vast opportunities to expand its cutting-edge research and development capabilities. This relocation not only benefits the company but also enhances White City Place’s reputation as a leading site for biotechnology advancements.
The Strategic Choice of White City
Synthace’s decision to move to White City was driven by the area’s vibrant life science ecosystem. The facilities offered here, combined with the commitment of developers Stanhope and Mitsui Fudosan to life sciences, present an ideal environment for innovative companies to flourish.
Tim Fell, CEO of Synthace, highlighted the advantages of being surrounded by leading names in tech and life sciences, which provides a synergistic atmosphere for growth. “The advantages of being within a vibrant life science and tech hub are of huge benefit to a dynamic company like ours,” he stated.
Synthace’s Innovative Contributions
Synthace is renowned for its leading cloud software platform which automates and improves the success rate of biological research and development.
Their technology is pivotal in driving advancements in the ‘Lab of the Future’, where automation, artificial intelligence, and biotechnology converge to accelerate research processes and reduce costs.
The company’s innovations have garnered significant recognition; Synthace was named one of the World’s 30 most promising Technology Pioneers by the World Economic Forum, and it was also selected as a Gartner ‘Cool Vendor in Life-Sciences’.
Growth and Recognition
After securing a £7.3 million Series-A funding round in 2017, Synthace has seen remarkable growth, doubling in size and appointing Silicon Valley veteran Bob Wiederhold as chairman. These strategic moves underscore its ambition to lead in computer-aided biology.
The expansion reflects the broader trend of growth in the biotech sector, with Synthace positioned as a key player in shaping the future of life sciences through technological innovation and leadership.
White City Place: A Biotech Powerhouse
The WestWorks building, now home to Synthace, also hosts other major companies such as Autolus, strengthening White City’s position as a nucleus for thriving biotech and biopharmaceutical enterprises.
The presence of these industry leaders is transforming White City Place into a destination for companies committed to pioneering advancements and creating an ecosystem conducive to collaboration and growth.
Infrastructure and Support
David Camp, chief executive of Stanhope, expressed enthusiasm about Synthace’s arrival, indicating its contribution to the area’s burgeoning knowledge economy.
Knight Frank and Cushman & Wakefield represented Stanhope in the deal, while Colliers International Life Sciences acted for Synthace, showcasing the collaboration between real estate and biotech sectors in supporting industry growth.
Looking Forward
As Synthace settles into its new premises, the future looks promising for both the company and White City as a whole.
Synthace’s move to White City represents not just a physical relocation but a strategic alignment with a community that values innovation and growth.
With a firm foundation in place, the company and its new hub are set to thrive in an ever-evolving scientific landscape.
